ReviewJournal of clinical immunology2007

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Thomas A WaldmannPubMed ↗Publisher ↗

No numbers read from the abstract.